Post-earnings recap
Reported
Thu, May 4, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.79 per share, but the stock still saw a slight increase of 0.62%. This could indicate that investors were not overly concerned about the loss or were optimistic about future developments. However, without any guidance or management commentary, the outlook remains uncertain.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.79 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.